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INTRODUCTION
The “Journey to the West”, Wu Cheng En’s work of
fiction from the 16th century Ming dynasty, relates the
trials and tribulations of a monk in his quest of
Buddhism scripture [1]. This popular narrative stands
as one of the four classics of Chinese literature. Such
work is in fact based on the true story of Tang dynasty
monk Xuan Zang, nearly 10 centuries earlier, who
traveled for 16 years on the Silk Road to India on his
quest [2,3]. Xuan Zang spent the 19 remaining years
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The pathological diagnosis of IgA nephropathy is straightforward and based on the distinctive mesangial
deposition of dominant IgA-containing immune complexes, even though the pathogenesis is poorly understood
and appears to be heterogeneous. The importance of clinical and morphological prognostic factors cannot be
overemphasized. The chronicity-based histological grading of IgA nephropathy is stressed for its predictive
impact and close correlation with the protracted course and disease progression. Extrapolation of the chronicity-
base grading of IgA nephropathy to all other chronic nephritis is inferred, linking a fictional approach to the
facts. The second topic describes the ongoing characterization of the isolated thick glomerular capillary basement
membrane (TGCBM), which has accumulated sufficient attributes to link such a renal lesion to the metabolic
syndrome. While the full significance of TGCBM remains to be investigated, as a marker of the metabolic
syndrome, its recognition and diagnosis may have a preventive impact on the complications arising from the
worldwide epidemic of diabetes and obesity. [Hong Kong J Nephrol 2008;10(2):50–7]
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of his life translating the scriptures and writing some
of the fundamentals of Buddhism in China [2,3]. To
this day, there have been constant rediscoveries of the
facts based on the interest shown in the fictional work.
Such interaction between fact and fiction contributed
to the better understanding of Xuan Zang and of his
work [1–3]. It is in this spirit that we approach the two
selected topics: one on the chronicity-based grading of
IgA nephropathy (IgAN) as a model, the other on the
thick glomerular capillary basement membrane
(TGCBM) as a marker for a syndrome.
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ON THE CHRONICITY-BASED GRADING OF IGAN
MODEL
The pathological diagnosis of IgAN is usually
straightforward and based on the mesangial deposition
of dominant IgA-C3 immune complexes, a rather
distinctive pattern which defines the disease (Figure 1)
[4–6]. Only minor diagnostic issues may arise from
immunofluorescence microscopy, for example when
other mesangial immunoreactants, IgG, IgM, C1q, are
also present in substantial amounts, which requires
excluding lupus nephritis. In advanced stages of
glomerulosclerosis, capillary tufts are distorted and may
blur the mesangial distribution of IgA-C3, in which case
only a presumptive diagnosis can be made.
The spectrum of glomerular lesions observed in
IgAN is relatively broad, though it is far from the
diversity encountered in lupus nephritis [7–10]. There
have been many histological classifications and grading
proposed for IgAN, but none have prevailed and no
consensus has been reached [7,8,11–16]. Difficulties
in consensus are explained by the divergent approaches
to classification from the “splitters” and the “lumpers”,
and also by geographic differences in the prevalence
of certain lesions, itself dependent on biopsy policy [7,
13–17]. Active glomerular lesions, such as necrosis,
are relatively uncommon, varying from 5% to 20% in
different series, and cellular crescents are rare. While
these active lesions may affect the course of the disease
and require therapy, they do not represent independent
predictors of renal survival, probably due to their low
prevalence [7,8,14–18].
Our approach to the histological grading of IgAN
is based on the notion that the condition is chronic and
progressive, and relates to the most prevalent glomerular
sclerosis, tubular atrophy, and interstitial fibrosis, all
chronic renal lesions, which are seemingly irreversible,
and cumulative [8,11,15,17,18]. This approach is akin
to the lumpers, focusing on prevalent and clinically
pertinent chronic lesions [7,8,11,17,18]. Glomerular
sclerosis refers to accumulation of mesangial and
basement membrane matrices, associated in varying
degree with capillary collapse, capillary hyalinosis,
capsular adhesion and glomerular tuft distortion (Fig-
ure 2) [8,17,18]. Its pathogenesis is incompletely
understood, but the role of inflammatory mediators such
as transforming growth factor-` (TGF-`), plasminogen
activator-inhibitor-1 (PAI-1), and platelet-derived
growth factors (PDGFs) appears to be important [19,
20]. The mechanisms leading to tubular atrophy and
interstitial fibrosis are also incompletely understood,
but they result partly from glomerulosclerosis and from
the activated inflammatory mediators induced by
chronic proteinuria [20,21]. Hyaline arteriosclerosis is
prevalent and closely related to hypertension, but its
pathogenesis is incompletely understood [18,20,22].
While some of the putative factors to these chronic
lesions can be modulated or altered by therapy, the
persistence of mesangial immune complexes argues for
the sustained injuries affecting glomeruli and tubules,
and consequently such chronic lesions appear
cumulative and irreversible, most accountable for the
protracted course and progression of IgAN (Figure 2)
[7,11,14,18,23,24].
Our chronicity-based histological grading of IgAN
evaluates three parameters: glomerular sclerosis, tubular
atrophy and interstitial fibrosis, and glomerular
arterioles [8,17,18]. As previously described,
glomerular sclerosis is assessed semiquantitatively: in
the first step, each glomerulus of a biopsy is categorized
as 0%, 25%, 50%, 75% and 100% for the extent of
Figure 1. Mesangial deposition of IgA-containing immune
complexes: (A) by immunofluorescence microscopy (FITC-labeled
anti-human IgA, 380×); (B) by immunoelectron microscopy (gold-
labeled anti-human IgA, lead citrate and uranyl acetate, 9,400×).
Figure 2. Morphological progression of IgA nephropathy from:
(A) an early stage with preserved glomerular capillary tuft
architecture; to (B) early segmental sclerosis and capsular adhesion;
to (C) severe segmental sclerosis exceeds 50% of glomerular tufts;
and finally to (D) global glomerulosclerosis (periodic acid-silver
methenamine, hematoxylin & eosin counterstain, all 360×).
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sclerosis for, respectively, when it is absent, not
exceeding 25%, 50%, 75% and exceeding 75% (Table
1). Next, sclerosis expressed in percentage (%) in all
glomeruli are added up, the sum obtained is divided by
the number of glomeruli, to provide the mean % of
sclerosis per glomerulus, which determines the
glomerular grade (GG) [8,17,18]. Tubulointerstitial
grade (TIG) estimates the extent of cortical scarring by
tubular atrophy and interstitial fibrosis in %, and
glomerular arterioles are graded for hyaline changes
(HA), irrespective of thickening of wall or luminal
reduction [8].
Tangible observations are the correlation of GG, TIG
and HA with serum creatinine, proteinuria and
hypertension at the time of biopsy, and of these
histological and clinical parameters with renal survival
[8,18]. By multivariate analysis, proteinuria, serum
creatinine at the time of biopsy, and GG represent
independent prognostic factors of renal survival [8].
Moreover, this grading is applicable to early IgAN,
when clinical manifestations are trivial, and chronic
lesions are absent or minimal, as it allows segregation
of patients with very low risk of progression from
others, an important stratification of patients useful in
therapeutic decision and clinical trials [7,18,25].
Despite the diversity of the many proposed
histological and clinical grading, there are in fact certain
agreement on clinical and morphological risk factors,
such as the relevance of proteinuria, renal function,
hypertension, glomerular sclerosis and tubulointerstitial
scarring, with differences only in the methods [7,8,12,
15,16]. On the strength of a grading system, D’Amico
emphasized a few aspects: (1) simple to apply, avoiding
tedious steps; (2) reproducible method, reflected in the
kappa value for interobserver and intraobserver
variation; (3) based on a sufficiently large non-selected
cohort; (4) a good and long follow-up; and (5) accurate
statistics in survival multivariate analysis of serial
clinical and histological parameters [7,8,15,16]. Our
chronicity-based histological grading meets these points
to be a suitable model [8,18].
In glomerulonephritis with a progressive course,
such as focal sclerosis, membranous nephropathy,
mesangiocapillary glomerulonephritis, IgAN/nephritis
of Henoch-Schonlein purpura and lupus nephritis, the
chronic renal lesions are commonly seen and constitute
a common denominator, though exacerbation of disease
course may be seen by the occurrence of acute lesions
[10,24,26,27]. The chronicity-based grading of IgAN
can be applied to such nephritis, even though the
severity of chronic lesions may vary, depending on the
stage of the disease, and the rate of progression may
differ. However, for any given nephritis, the predictive
value of the grading model can be adjusted or clinically
correlated with its own rate of disease progression.
We applied this IgAN chronicity-based grading to
57 patients with primary membranous nephropathy over
a median follow-up of 82 months, and found that GG,
TIG, proteinuria and impaired renal function at the time
of renal biopsy are all predictors of renal survival
(Figure 3). Although the study was based on a relatively
small cohort, the grading model may yield prognostic
information when applied to membranous nephropathy,
and potentially to other chronic glomerulonephritis. The
significance of applying a universal grading to different
chronic nephropathies includes the possibility to
compare the prevalence of such chronic lesions, the
prognostic risk among these nephritis, and their
response to therapeutic trials. It may appear fictional
to use it as a universal grading, and extrapolate it to
any nephropathies, but all other chronic nephritis share
with IgAN the ubiquitous chronic lesion, and why not
also sharing a good grading model (Figure 4) [10,12,
15,16,18,24,27].
Table 1. Chronicity-based grading (CBG) of IgA nephropathy*
Glomerular grading (GG), i.e. mean sclerosis per glomerulus
GG1a < 10%
GG1b 10% to < 25%
GG2 25% to < 50%
GG3 * 50%
Tubulointerstitial grading (TIG), i.e. tubular loss and interstitial
fibrosis
TIG1 < 5%
TIG2 5% to < 50%
TIG3 * 50%
Hyaline arteriosclerosis (HA)
Present or absent
*Minimum requirement for assessment: 10 glomeruli, 5 mm cortex,
3 arterioles.
Figure 3. Chronicity-based glomerular grading (GG) is correlated
with impaired renal function (IRF) on follow-up of patients with
primary membranous nephropathy.
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ON A MARKER FOR A SYNDROME–THE TGCBM
In recent years, an increasing number of patients
presenting with proteinuria, isolated or associated with
microscopic hematuria and hypertension, are
recognized for their distinctive lesion in renal biopsy
[28]. We have coined the renal lesion isolated TGCBM,
as the main histological finding in renal biopsy is a
diffusely thickened glomerular capillary basement
membrane (GCBM) only recognizable on electron
m i c r o s c o p y  ( F i g u r e  5 ) .  B o t h  l i g h t  a n d
immunofluorescence microscopy are unrevealing or
normal,  except for patients with underlying
hypertensive injury. In many cases, the global
thickening of the GCBM is readily recognized in routine
ultrastructure examination, but in other patients, the
thickening is mild or subtle, can be overlooked, and
goes unrecognized. In such cases, the renal biopsy may
be reported as hypertensive nephrosclerosis or minimal
change nephropathy, depending upon the level of
proteinuria or the clinical impression.
Two morphological criteria have to be met in order
to recognize and diagnose this isolated TGCBM lesion
[28]. One criterion is qualitative, requiring the
thickening of GCBM to be uniform, global and diffuse,
observed in the majority of capillary loops and in all
glomeruli (Figure 5). The other criterion is quantitative,
which uses computer-assisted imaging software for
ultrastructure morphometry, with direct linear
measurement of the GCBM [28]. This quantitative
method permits one to obtain a mean GCBM thickness,
based on a minimum of 200 non-random measurements
[28]. The mean GCBM thickness in adults was
established from 13 patients with a normal renal biopsy,
ranging from 346 nm to 396 nm, and from 35 adults
with minimal change nephropathy, ranging from 336
nm to 384 nm [28]. In practice, an adult with a uniform
GCBM exceeding a mean thickness of 400 nm will be
given a presumptive diagnosis of isolated TGCBM.
Such a lesion cannot be measured in glomeruli where
the GCBM shows immune deposition, or is wrinkled
and distorted in advanced nephrosclerosis, and patients
with diabetes and systemic lupus erythematosus are
excluded [28–30].
The number of cases identified by these criteria is
increasing, and up to now, 91 patients with at least a
mean 4-year follow-up have been diagnosed, exhibiting
clinical features very similar to the initial group of 23
patients reported [28]. The condition shows a slight
male prevalence (54:37) with a median age of 46 years
(age range, 15–84 years). All patients presented with
proteinuria with a median of 2.5 g/day (range, 0.5–
12.0 g/day), including 20% in the nephrotic range.
Microscopic hematuria was present in 38% of patients,
and hypertension in 62% of the cases. Two patients in
46 examined showed diabetic retinopathy. At the time
of biopsy, median serum creatinine was 115 +mol/L;
fasting blood glucose was normal in 75% of cases.
We found no correlation between isolated TGCBM
and smoking, age, body weight, blood pressure, fasting
blood glucose, and hyperlipidemia (present in a third of
the patients tested). However, at 48 months of follow-
up, 35% of patients showed elevated fasting blood
glucose, 38% showed either impaired glucose tolerance
or fasting glucose, or both, while 26% lacked evidence
of diabetes. The persistence of proteinuria observed in
all these patients indicates that TGCBM represents a
chronic renal condition, and the question raised is
Figure 5. Thick glomerular capillary basement membrane
consisting of uniform and homogeneous thickening of the basement
membrane, is a global and diffuse glomerular process, requiring
ultrastructural morphometry for diagnosis (lead citrate and uranyl
acetate, 6,400×).
Figure 4. Sclerosing process is accountable for disease progression
in membranous nephropathy (MGN), focal glomerulosclerosis
(FGS), mesangiocapillary glomerulonephritis (MCGN), and lupus
nephritis (LN), and represents the basic lesion for the application
of the IgAN grading model (periodic acid-silver methenamine,
hematoxylin & eosin counterstain, all 360×).
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whether such a condition progresses. None of these
patients were required to have a repeat renal biopsy to
permit the assessment of progression. However, during
the follow-up period, 16 patients (20%) developed
chronic renal failure with a serum creatinine level
exceeding 130 +mol/L, including four patients reaching
end-stage renal failure (5%). Clearly, isolated TGCBM
is strongly associated with pre-diabetes or diabetes, and
its chronicity mandates the determination of its prognosis.
TWO ISSUES ARE ADDRESSED HERE: IS TGCBM
A NEW CONDITION? WHAT IS THE CLINICAL
IMPORTANCE OF TGCBM?
(a)  As a histological  composite of diabetic
glomerulosclerosis, TGCBM is a well-known lesion,
closely associated with mesangial nodular sclerosis of
Kimmelstiel-Wilson, capillary exudations (so-called
fibrin caps and capsular drops) and hyaline
arteriosclerosis [29–31]. However, in patients with
isolated TGCBM, the condition can be regarded as new
and distinctive as the majority of patients do not show
evidence of diabetes at the time of biopsy [28]. The
appearance of features of diabetes on follow-up of these
patients argues for a relationship of isolated TGCBM
to pre-diabetes. This observation is important because
patients with proteinuria and isolated TGCBM are at a
stage where the appearance of diabetes can potentially
be delayed or prevented. From a pathogenetic
viewpoint, it is clear that the development of TGCBM
is unrelated to hyperglycemia or to its metabolic
disorders such as accumulation of advanced glycation
end products and activation of protein kinase C, widely
perceived as mechanisms underlying diabetic
glomerular lesions [28,29,31]. Thus, the mechanisms
leading to the development of TGCBM needs to be
revisited and elucidated.
(b) Among the multiple mechanisms evoked in the
development of diabetic nephropathy, apart from
hyperglycemia and glycated proteins, hemodynamic
alteration and hyperfiltration, as well as oxidative stress
are viewed as key factors [31–33]. In the absence of
hyperglycemia, a state of insulin resistance and
hyperinsulinemia, as well as genetic susceptibility
appear to play an important role [31–33]. As a
consequence of these factors, upregulation of growth
factors and cytokines, such as TGF-`1 and insulin-like
growth factor I (ILG-I), takes place as an important
downstream mediator for the development of renal
hypertrophy, GCBM thickening and accumulation of
mesangial matrix [31–33]. Podocytes are regarded as a
central target for the effects of the metabolic or diabetic
milieu, and the resulting podocytopathy upregulates
vascular endothelial growth factor (VEGF), causing the
alteration of vascular permeability [32,33].
(c) We examined the possible relationship between
isola ted TGCBM and insul in  res is tance or
hyperinsulinemia, as suggested by the association of
this renal lesion with pre-diabetes, and by the evidence
of such a relationship in an experimental model [34,
35]. Serum insulin levels and the homeostatic model
assessment (HOMA) for basal insulin resistance were
examined in 24 non-diabetic patients with isolated
TGCBM (Table 2), as well as in 51 patients with IgAN,
12 of whom have TGCBM and 39 a normal GCBM
thickness (Table 3) [36,37]. The HOMA is a
mathematical model based on simultaneous fasting
plasma glucose and fasting serum insulin levels to
calculate insulin sensitivity and ` -cell function [36,37].
Table 2. Insulin resistance in 24 patients with thick glomerular
capillary basement membrane*
GCBM thickness (nm) 468 (408–659)
Proteinuria at biopsy (g/day) 1.8 (0.4–3.9)
Serum creatinine at biopsy (+mol/L) 110 (52–230)
Impaired renal function† 5/24 (21)
Follow-up period (mo) 45 (5–88)
Fasting serum insulin (pmol/L) 64.7 (6.8–144.6)
Hyperinsulinemia‡ 15/24 (62.5)
Fasting HOMA 2.13 (0.31–5.07)
Insulin resistance§ 13/24 (54.2)
Diabetic at follow-up 3/19 (16)
Abnormal oral glucose tolerance test 5/19 (36)
Last serum creatinine at follow-up (+mol/L) 116 (60–500)
Impaired renal function at last follow-up† 5/24 (21)
*Data are presented as mean (range) or number of cases (%);
†serum creatinine > 130 +mol/L; ‡fasting insulin > 60 pmol/L;
§HOMA index > 2.42 in males and > 2.08 in females. GCBM =
glomerular capillary basement membrane; HOMA = Homeostasis
Assessment Model [36].
Table 3. Insulin resistance in 51 patients with IgA nephropathy*
Thickened GCBM 12/39
Age (yr) 36.4 (16–54)
Sex (M:F) 18:36
Proteinuria at biopsy (g/day) 2.2 (0.2–10.5)
Serum creatinine at biopsy (+mol/L) 109 (50–413)
Impaired renal function at biopsy† 9/46 (20)
Follow-up period (mo) 40 (6–78)
Hyperinsulinemia‡ 14/51 (28)
Insulin resistance§ 8/51 (16)
Diabetic at follow-up 3/24 (13)
Abnormal oral glucose tolerance test 1/24 (4)
Impaired renal function at last follow-up† 9/51 (18)
*Data are presented as mean (range) or number of cases (%);
†serum creatinine > 130 +mol/L; ‡fasting insulin > 60 pmol/L;
§HOMA index > 2.42 in males and > 2.08 in females. GCBM =
glomerular capillary basement membrane; HOMA = Homeostasis
Assessment Model [36].
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Hyperinsulinemia, defined in patients with a fasting
serum insulin level exceeding 60 pmol/L, was observed
in 15 of 24 patients with TGCBM (62.5%). Insulin
resistance, defined in male patients by a HOMA index
exceeding 2.42 and in female patients by a HOMA
index exceeding 2.08, was found in 13 (54.2%) patients
[36,37]. However, both serum insulin levels and insulin
resistance were not correlated with sex, age, TGCBM
or development of diabetes or impaired glucose
tolerance on follow-up. In patients with IgAN, fasting
hyperinsulinemia was seen in 14 of 51 patients (28%),
and insulin resistance was found in 8 of the 51 cases
(16%). Similarly, both serum insulin and insulin
resistance were not correlated with sex, age, TGCBM
or development of diabetic features. Nevertheless, as a
group, TGCBM patients compared to IgAN patients
showed a significantly higher fasting hyperinsulinemia
(p = 0.04, r2 test) and insulin resistance (p = 0.01, r2
test), respectively, and predicted the development of
diabetes or impaired glucose tolerance (p = 0.049,
Fisher’s exact test). While these preliminary
observations do not support a determining role of
hyperinsulinemia or insulin resistance in the genesis
of TGCBM, their contribution as one of the
multifactorial mechanisms remains to be considered.
(d) In the clinical characterization of these patients
with proteinuria and isolated TGCBM, the fact that a
proportion to a majority of these patients demonstrate
hypertension, pre-diabetes or diabetes, hyperlipidemia,
hyperinsulinemia and insulin resistance, makes it
evident that isolated TGCBM represents not only the
renal lesion of pre-diabetes, but more specifically the
renal marker of the metabolic syndrome [37–39]. In
patients with metabolic syndrome, apart from their
critical risk for complications of cardiovascular disease,
a common association with some form of chronic
kidney disease is increasingly recognized, and
evidenced by persistence of proteinuria and reduction
in glomerular filtration rate, even in the absence of
diabetes [38–40]. Currently, no information on the
pathology of such chronic kidney disease is available,
and hence a prospective renal biopsy study in patients
with metabolic syndrome may help not only to confirm
whether TGCBM is indeed the renal lesion of this
syndrome, but also whether other associated renal
lesions exist.
(e) There are so far two important clinical
observations made among these patients with chronic
renal disease and isolated TGCBM. One is that
approximately 5% of them progressed to end-stage
renal failure within a period of 4–5 years, and while
renal failure is attributed to hypertension and
atherosclerosis, the exact mechanism is uncertain.
Approximately 20% of the patients showed impaired
renal function at the time of biopsy, and most
improved on follow-up, while about 20% of patients
developed impaired renal function on follow-up
despite treatment of hypertension and management.
This second observation suggests that chronic renal
disease associated with TGCBM can improve or
stabilize on management of the metabolic syndrome,
and indicates the potential to prevent progression to
full blown diabetic nephropathy or end-stage disease.
Whether the TGCBM lesion is reversible or its
progression preventable remains to be investigated,
though this has been suggested in the animal model
[34,35].  Ongoing cl inical  and experimental
investigations on angiotensin receptor blockers and
thiazolidinediones, which alter cell insulin receptor
response, also implicate the role of certain tissue
growth factors in the development of glomerulomegaly
and TGCBM for their interaction with insulin
resistance [35,41]. Studies focusing on serum and
tissue growth factors and their correlation with
TGCBM may further elucidate their role in the
development of the renal lesion and injury.
(f) Last but not least, the diagnosis of TGCBM
relies on electron microscopy and ultrastructure
morphometry, a procedure not familiar to most
diagnostic pathologists, without which the renal lesion
goes unrecognized, and the biopsy reported as
hypertensive nephrosclerosis or minimal change
nephropathy, depending on the clinical correlation,
as  in  TGCBM the prote inur ia  ranges  f rom
microalbuminuric to nephrotic levels. Moreover,
TGCBM may not occur alone; we have recognized it
in patients with IgAN and in patients on steroid
treatment such as those with allograft or steroid-
dependent minimal change nephropathy.
SUMMARY
Isolated TGCBM is a form of chronic renal disease,
probably representing the renal lesion associated with
the metabolic syndrome. Its increasing incidence may
parallel the worldwide epidemic of diabetes or
metabolic syndrome. Disease progression is evident,
but its prevalence remains to be seen. Clinical
improvement is observed, suggesting the potential for
reversibility, but its pathogenesis is poorly understood,
multifactorial, and unrelated to hyperglycemia.
Ultrastructure morphometry is required for diagnosis.
TGCBM may superimpose to other renal lesions.
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